|
何大一教授昨在沪表示 艾滋病疫苗研发成全球热点
■文汇报 记者陈青 报道
本报讯 疫苗研究已成为全球艾滋病研究领域中最大的热点。昨天，美国艾伦·戴蒙得研究中心主任何大一教授在由上海市公共卫生中心主办的“艾滋病机会感染国际研讨会”上透露，由他领导的研究小组经过6年努力，在艾滋病疫苗研究方面取得了可喜进展。其中最早的两种疫苗，即核酸疫苗和载体疫苗已完成了93例的一期临床试验，在18个月的随访中,93名志愿者未出现异常反应，具有较好的安全性。
何大一说，一种疫苗的成功研发最起码要花10年时间，研究小组分别花了3年和4年的时间才让核酸疫苗、载体疫苗从实验室阶段进入临床试验阶段。目前另3种新的艾滋病疫苗尚处于实验室阶段。
三年前，何大一将核酸疫苗和载体疫苗捐赠给我国卫生部，并与中国医学科学院开展了全面合作，目前我国已具备生产这两种疫苗的技术。据悉，近期有关部门将向国家食品药品监督管理局提出申请，一旦获准将进入临床试验。
Professor He Dayi said yesterday in Shanghai AIDS vaccine research and development into a global hot spots
■ Wenhui newspaper reporters Chen Qing and Bao Dao
A vaccine research has become a global field of AIDS research biggest hot spots. Yesterday, the United States Aaron Diamond Research Center, a Professor He Dayi, director at the Shanghai Public Health Center-sponsored "International Symposium on AIDS, opportunistic infections," said on his leadership of the Group after 6 years of hard work, in the AIDS vaccine Research has made gratifying progress. One of the first two vaccines, that is, nucleic acid vaccines and vector vaccines have been completed and 93 cases of a clinical trial at 18 months of follow-up, 93 volunteers are not abnormal reactions, has better security.
Ho said that the success of a vaccine R & D spend at least 10 years, Group 3, respectively, spent 4 years and years to allow nucleic acid vaccines, vector vaccine from the laboratory stage to clinical trials. At present, the other three kinds of new AIDS vaccine is still at the laboratory stage.
Three years ago, Ho will be nucleic acid vaccines and vector vaccines donated to China's Ministry of Health and Chinese Academy of Medical Sciences carried out all-round cooperation, China has both vaccine production technology. It is reported that recently the relevant departments to the State Food and Drug Administration to apply, once allowed to enter clinical trials.
|
